Nacelle Therapeutics, Inc.

Manhattan, KS 66502

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $528K
First Award Date 05/10/02
Most Recent Award Date 06/01/04

Key Personnel

Last Name Name Awards Contact
Tomich John M Tomich 3

3 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/04 - 05/31/05

DESCRIPTION (provided by applicant) The innovative use of a synthetic peptide to modulate epithelial cell-cell interactions is proposed for the augmentation of drug- or gene-based therapeutic interventions. Cell monolayers are a major obstacle to delivering drugs to selected locations throughout the body. Transient access to these compartments w...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/20/02 - 06/30/03

DESCRIPTION (provided by applicant): The innovative use of a synthetic peptide to modulate epithelial or endothelial cell-cell interactions is proposed for the augmentation of drug- or gene-based therapeutic interventions. Cell monolayers are a major obstacle to delivering drugs to selected locations throughout the body. Transient access to the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/10/02 - 01/31/06

DESCRIPTION (Applicant's abstract): Nacelle's overall objective is to develop and commercialize a superior cystic fibrosis (CF) therapeutic, derived from a family of unique peptides that will form functional ion channels in defective cell membranes. Nacelle Therapeutics refers to this treatment modality as "Peptide-based channel replacement ther...